BIOMAT Database Logo BIOMAT Database Logo

Effect and compatibility of isovolaemic haemodilution in the treatment of ischaemic and non-ischaemic central retinal vein occlusion. 1989

L L Hansen, and J Wiek, and M Schade, and N Müller-Stolzenburg, and M Wiederholt
Department of Ophthalmology, Klinikum Steglitz, Freie Universität, Berlin.

In a prospective study, 48 eyes with non-ischaemic and 35 with ischaemic central retinal vein occlusion (CRVO) were treated by isovolaemic haemodilution (IHD). Two or more cardiovascular risk factors were present in 42% of patients with non-ischaemic and in 69% of patients with ischaemic CRVO (p less than 0.025). Nevertheless, IHD in no case caused serious cardiovascular complications. Minor problems were short fainting spells in 5% and a general weakness in 16% of the haemodiluted patients. The effect of IHD was measured by determining the time of maximal venous filling (tmvf) in fluorescein angiographies. Lowering the packed cell volume to 32-35% accelerated the tmvf from 18.4 +/- 1.61 to 13.1 +/- 1.0 s (p less than 0.001) in eyes with non-ischaemic CRVO and from 24.5 +/- 1.2 to 14.8 +/- 1.3 s (p less than 0.001) in eyes with ischaemic CRVO. After 3 months, an increase in visual acuity had occurred in 27% of eyes with non-ischaemic CRVO and in 48.5% with ischaemic CRVO. These improvement rates could nearly be maintained after 1 year. 59% of eyes with non-ischaemic and 25% with ischaemic CRVO were able to read (visual acuity greater than or equal to 6/15) after 1 year.

UI MeSH Term Description Entries
D007511 Ischemia A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION. Ischemias
D008028 Light Coagulation The coagulation of tissue by an intense beam of light, including laser (LASER COAGULATION). In the eye it is used in the treatment of retinal detachments, retinal holes, aneurysms, hemorrhages, and malignant and benign neoplasms. (Dictionary of Visual Science, 3d ed) Photocoagulation,Coagulation, Light,Coagulations, Light,Light Coagulations,Photocoagulations
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D002318 Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM. Adverse Cardiac Event,Cardiac Events,Major Adverse Cardiac Events,Adverse Cardiac Events,Cardiac Event,Cardiac Event, Adverse,Cardiac Events, Adverse,Cardiovascular Disease,Disease, Cardiovascular,Event, Cardiac
D005451 Fluorescein Angiography Visualization of a vascular system after intravenous injection of a fluorescein solution. The images may be photographed or televised. It is used especially in studying the retinal and uveal vasculature. Fluorescence Angiography,Fundus Fluorescence Photography,Angiography, Fluorescein,Angiography, Fluorescence,Fluorescence Photography, Fundus,Photography, Fundus Fluorescence
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006400 Hematocrit The volume of packed RED BLOOD CELLS in a blood specimen. The volume is measured by centrifugation in a tube with graduated markings, or with automated blood cell counters. It is an indicator of erythrocyte status in disease. For example, ANEMIA shows a low value; POLYCYTHEMIA, a high value. Erythrocyte Volume, Packed,Packed Red-Cell Volume,Erythrocyte Volumes, Packed,Hematocrits,Packed Erythrocyte Volume,Packed Erythrocyte Volumes,Packed Red Cell Volume,Packed Red-Cell Volumes,Red-Cell Volume, Packed,Red-Cell Volumes, Packed,Volume, Packed Erythrocyte,Volume, Packed Red-Cell,Volumes, Packed Erythrocyte,Volumes, Packed Red-Cell
D006438 Hemodilution Reduction of blood viscosity usually by the addition of cell free solutions. Used clinically (1) in states of impaired microcirculation, (2) for replacement of intraoperative blood loss without homologous blood transfusion, and (3) in cardiopulmonary bypass and hypothermia. Hemodilutions
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012170 Retinal Vein Occlusion Blockage of the RETINAL VEIN. Those at high risk for this condition include patients with HYPERTENSION; DIABETES MELLITUS; ATHEROSCLEROSIS; and other CARDIOVASCULAR DISEASES. Branch Retinal Vein Occlusion,Branch Vein Occlusion,Central Retinal Vein Occlusion,Retinal Branch Vein Occlusion,Thrombosis, Retinal Vein,Retinal Vein Thrombosis,Branch Vein Occlusions,Occlusion, Branch Vein,Occlusion, Retinal Vein,Retinal Vein Occlusions,Retinal Vein Thromboses,Vein Occlusion, Branch,Vein Occlusion, Retinal,Vein Thrombosis, Retinal

Related Publications

L L Hansen, and J Wiek, and M Schade, and N Müller-Stolzenburg, and M Wiederholt
Effect of isovolaemic haemodilution on visual outcome in branch retinal vein occlusion.
February 1998, The British journal of ophthalmology,
L L Hansen, and J Wiek, and M Schade, and N Müller-Stolzenburg, and M Wiederholt
A randomised prospective study on treatment of central retinal vein occlusion by isovolaemic haemodilution and photocoagulation.
February 1985, The British journal of ophthalmology,
L L Hansen, and J Wiek, and M Schade, and N Müller-Stolzenburg, and M Wiederholt
Arterio-venous dissection after isovolaemic haemodilution in branch retinal vein occlusion: a non-randomised prospective study.
July 2006, Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie,
L L Hansen, and J Wiek, and M Schade, and N Müller-Stolzenburg, and M Wiederholt
Ischaemic central retinal vein occlusion in the young.
January 1993, Eye (London, England),
L L Hansen, and J Wiek, and M Schade, and N Müller-Stolzenburg, and M Wiederholt
Early intravitreal bevacizumab for non-ischaemic central retinal vein occlusion.
February 2009, Acta ophthalmologica,
L L Hansen, and J Wiek, and M Schade, and N Müller-Stolzenburg, and M Wiederholt
[Treatment of central retinal vein occlusion].
January 1992, Journal francais d'ophtalmologie,
L L Hansen, and J Wiek, and M Schade, and N Müller-Stolzenburg, and M Wiederholt
Treatment of central retinal vein occlusion.
July 1997, Ophthalmic surgery and lasers,
L L Hansen, and J Wiek, and M Schade, and N Müller-Stolzenburg, and M Wiederholt
Glaucoma as a prognostic factor of central retinal vein occlusion: visual and anatomical outcomes and occurrence of ischaemic central retinal vein occlusion.
June 2021, Acta ophthalmologica,
L L Hansen, and J Wiek, and M Schade, and N Müller-Stolzenburg, and M Wiederholt
Anterior ischaemic optic neuropathy associated with central retinal vein occlusion.
August 2000, Eye (London, England),
L L Hansen, and J Wiek, and M Schade, and N Müller-Stolzenburg, and M Wiederholt
Electroretinographic findings versus fluorescein angiographic appearance of the retina in patients with ischaemic and non-ischaemic central retinal vein occlusion.
January 1995, Bulletin de la Societe belge d'ophtalmologie,
Copied contents to your clipboard!